{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:24:21Z","timestamp":1794349461083,"version":"4.9.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003803","name":"University of Hong Kong","doi-asserted-by":"publisher","award":["2407102490"],"award-info":[{"award-number":["2407102490"]}],"id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["17210226"],"award-info":[{"award-number":["17210226"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["17209225"],"award-info":[{"award-number":["17209225"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001839","name":"University Grants Committee","doi-asserted-by":"publisher","award":["R7007-22"],"award-info":[{"award-number":["R7007-22"]}],"id":[{"id":"10.13039\/501100001839","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.isci.2026.117536","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:20:40Z","timestamp":1789636840000},"page":"117536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting disease progression and mortality in prostate cancer using real-world data-driven time-inhomogeneous Markov models"],"prefix":"10.1016","volume":"29","author":[{"given":"Jiaqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanshi","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Wai","family":"Kwan Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Makram","family":"Bishai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7470-5108","authenticated-orcid":false,"given":"Rong","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-7808","authenticated-orcid":false,"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117536_bib1","series-title":"StatPearls","article-title":"Prostate Cancer","author":"Leslie","year":"2024"},{"key":"10.1016\/j.isci.2026.117536_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s44197-023-00103-6","article-title":"Global Burden of Prostate Cancer and Association with Socioeconomic Status, 1990-2019: A Systematic Analysis from the Global Burden of Disease Study","volume":"13","author":"Zhang","year":"2023","journal-title":"J. Epidemiol. Glob. Health"},{"key":"10.1016\/j.isci.2026.117536_bib3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2016.08.065","article-title":"The CAPRA score at 10 years: contemporary perspectives and analysis of supporting studies","volume":"71","author":"Brajtbord","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2026.117536_bib5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12916-020-01681-z","article-title":"PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment","volume":"18","author":"Devos","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.isci.2026.117536_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228447","article-title":"Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study","volume":"15","author":"Thomsen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.117536_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16173029","article-title":"Traditional Prostate Cancer Risk Assessment Scales Do Not Predict Outcomes from Brain Metastases: A Population-Based Predictive Nomogram","volume":"16","author":"Ladner","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.117536_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512508","article-title":"Can We Predict Prostate Cancer Metastasis Based on Biomarkers? Where Are We Now?","volume":"24","author":"San Francisco","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.117536_bib9","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1002\/sim.8998","article-title":"A multistate survival model of the natural history of cancer using data from screened and unscreened population","volume":"40","author":"Bhatt","year":"2021","journal-title":"Stat. Med."},{"key":"10.1016\/j.isci.2026.117536_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/17407745241267862","article-title":"Using multistate models with clinical trial data for a deeper understanding of complex disease processes","volume":"21","author":"Therneau","year":"2024","journal-title":"Clin. Trials"},{"key":"10.1016\/j.isci.2026.117536_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277282","article-title":"Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer","volume":"17","author":"Barbier","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.117536_bib12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer","volume":"2","author":"Sathianathen","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.isci.2026.117536_bib13","article-title":"Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Public Health"},{"key":"10.1016\/j.isci.2026.117536_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32080412","article-title":"Systematic Literature Review on Economic Evaluations and Health Economic Models in Metastatic Castration-Sensitive Prostate Cancer","volume":"32","author":"Nguyen","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.isci.2026.117536_bib15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117536_bib16","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2011.35.8648","article-title":"End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice","volume":"29","author":"Scher","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117536_bib17","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","author":"Chandrasekar","year":"2015","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.isci.2026.117536_bib18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.isci.2026.117536_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2026.117536_bib20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11523-022-00899-6","article-title":"Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry","volume":"17","author":"Verry","year":"2022","journal-title":"Target. Oncol."},{"key":"10.1016\/j.isci.2026.117536_bib21","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41416-022-01904-5","article-title":"Multistate models for the natural history of cancer progression","volume":"127","author":"Cheung","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.117536_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-016-0046-1","article-title":"Advances in hormonal therapies for hormone na\u00efve and castration-resistant prostate cancers with or without previous chemotherapy","volume":"5","author":"Pham","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117536_bib23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117536_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2026.117536_bib25","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1038\/s41598-023-32987-6","article-title":"Machine-learning predicts time-series prognosis factors in metastatic prostate cancer patients treated with androgen deprivation therapy","volume":"13","author":"Saito","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117536_bib26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00345-015-1691-4","article-title":"PREDICT: model for prediction of survival in localized prostate cancer","volume":"34","author":"Kerkmeijer","year":"2016","journal-title":"World J. Urol."},{"key":"10.1016\/j.isci.2026.117536_bib27","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/jnci\/djp122","article-title":"Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis","volume":"101","author":"Cooperberg","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.isci.2026.117536_bib28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/biostatistics\/kxaa030","article-title":"General tests of the Markov property in multi-state models","volume":"23","author":"Titman","year":"2022","journal-title":"Biostatistics"},{"key":"10.1016\/j.isci.2026.117536_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020270","article-title":"Multistate Markov Model to Predict the Prognosis of High-Risk Human Papillomavirus-Related Cervical Lesions","volume":"12","author":"Taguchi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.117536_bib30","doi-asserted-by":"crossref","first-page":"e968","DOI":"10.1016\/S2214-109X(19)30201-3","article-title":"Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model","volume":"7","author":"Tang","year":"2019","journal-title":"Lancet. Glob. Health"},{"key":"10.1016\/j.isci.2026.117536_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40471-022-00291-y","article-title":"The Utility of Multistate Models: A Flexible Framework for Time-to-Event Data","volume":"9","author":"Le-Rademacher","year":"2022","journal-title":"Curr. Epidemiol. Rep."},{"key":"10.1016\/j.isci.2026.117536_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/medsci8030028","article-title":"Epidemiology, Staging and Management of Prostate Cancer","volume":"8","author":"Barsouk","year":"2020","journal-title":"Med. Sci."},{"key":"10.1016\/j.isci.2026.117536_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.656444","article-title":"Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy","volume":"11","author":"Mandel","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117536_bib34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00259-020-04981-x","article-title":"PSMA whole-body tumor burden in primary staging and biochemical recurrence of prostate cancer","volume":"48","author":"Santos","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.isci.2026.117536_bib35","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2589-7500(20)30314-9","article-title":"Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database","volume":"3","author":"Lee","year":"2021","journal-title":"Lancet Digit. Health"},{"key":"10.1016\/j.isci.2026.117536_bib36","article-title":"Projecting the 10-year costs of care and mortality burden of depression until 2032: a Markov modelling study developed from real-world data","volume":"45","author":"Chan","year":"2024","journal-title":"Lancet Reg. Health West. Pac."},{"key":"10.1016\/j.isci.2026.117536_bib37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/jop.13045","article-title":"Bayesian disease mapping and the 'High-Risk' oral cancer population in Hong Kong","volume":"49","author":"Adeoye","year":"2020","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.isci.2026.117536_bib38","article-title":"The trends in lung cancer prevalence, incidence, and survival in Hong Kong over the past two decades (2002-2021): a population-based study","volume":"45","author":"Au","year":"2024","journal-title":"Lancet Reg. Health West. Pac."},{"key":"10.1016\/j.isci.2026.117536_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112249","article-title":"Real-world effectiveness of novel hormonal agents and docetaxel in patients with prostate cancer: A head-to-head comparison","volume":"28","author":"Jiao","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.isci.2026.117536_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/joim.13590","article-title":"Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin","volume":"293","author":"Shami","year":"2023","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.isci.2026.117536_bib41","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/jop.13454","article-title":"Predicting oral cancer survival-Development and validation of an Asia-Pacific nomogram","volume":"52","author":"Wang","year":"2023","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.isci.2026.117536_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003880","article-title":"Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: A cohort study","volume":"19","author":"Yu","year":"2022","journal-title":"PLoS Med."},{"key":"10.1016\/j.isci.2026.117536_bib43","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","article-title":"Impact of comorbidity on survival among men with localized prostate cancer","volume":"29","author":"Albertsen","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117536_bib44","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1002\/cncr.26392","article-title":"Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality","volume":"118","author":"Scosyrev","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.isci.2026.117536_bib45","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1200\/JCO.2016.70.7794","article-title":"Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study","volume":"35","author":"Rajan","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226029159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226029159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:50:18Z","timestamp":1794347418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226029159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2589004226029159"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117536","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting disease progression and mortality in prostate cancer using real-world data-driven time-inhomogeneous Markov models","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117536"}}